Article Text

Download PDFPDF
Metabolic syndrome common in people with psychotic disorders, particularly in users of high potency antipsychotics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Jaana Suivisaari

Correspondence to: Jaana Suivisaari, Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland;



What is the prevalence of metabolic syndrome in people with psychotic disorders or using antipsychotic medications?


Subset of 5434 people (aged over 30 years) enrolled in the Health 2000 Study who had available measurements relating to metabolic syndrome that were taken after fasting for 4 hours.


Primary care settings across 80 municipalities in Finland; recruitment September 2000 to June 2001.


People who were screened positive for a possible psychotic disorder (reported a diagnosis, showed signs of psychotic or manic symptoms during health examination) were interviewed using the research version of the Structured Clinical Interview for DSM-IV-TR to diagnose psychotic disorders. Diagnoses were classified as schizophrenia, other non-affective psychotic disorders (including schizophreniform and schizoaffective disorder), and affective psychosis (bipolar I disorder and major depressive disorder with psychotic symptoms). Diagnosis of metabolic syndrome was made if people fulfilled ⩾3 NECP ATP-III criteria: fasting triglycerides ⩾150 mg/dl; waist circumference >88 cm in women or >102 cm in …

View Full Text


  • Source of funding: Grants from Stanley Medical Research Institute, Yrjo Jahnsson Foundation, and the Academy of Finland.

  • ▸ Additional notes and a reference list are published online only at


  • Competing interests: SS has received honoraria for lectures from Eli Lilly, Astra Zeneca, Bristol Myers Squibb and Janssen, and educational grants from Eli Lilly and Astra Zeneca.